ROS1 and neoplasm: Repotrectinib (TPX-0005), another next-generation ROS1/TRK/ALK inhibitor, has shown promising anti-tumor activity, a confirmed partial response (reduced by 82%) in an entrectinib-resistant patient with a salivary gland tumor and a tumor regression (reduced by 33%) in a patient with larotrectinib-resistant cholangiocarcinoma were reported [103].